Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Higher Prevalence of Tremor in Patients with Amyloidosis Than in the General Population
Movement Disorders
P15 - Poster Session 15 (12:00 PM-1:00 PM)
3-003
To determine the prevalence of tremor in patients with amyloidosis.
The Amyloidosis Center at Boston University School of Medicine and Boston Medical Center specializes in evaluation, treatment, and research in patients with all subtypes of amyloidosis. The interdisciplinary clinic includes evaluation by a neuromuscular neurologist. These neurologists have observed that patients with amyloidosis are prone to a tremor resembling essential tremor (ET) (presenting with action and posture in hands or a voice tremor). While ET is the most common movement disorder, we sought to determine if patients with amyloidosis are more likely to have tremor than the general population.
Data was obtained from patients seen in the amyloidosis center between January 2013 to September 2018. All patients with amyloidosis were queried including patients with systemic immunoglobulin light-chain (AL) amyloidosis, hereditary transthyretin amyloidosis (ATTRv) and wild type (ATTRwt). Each chart was reviewed for documentation of the word “tremor” in clinical notes. Descriptive analysis was then performed.
821 patients were seen during this time frame. Of these, 15 patients were excluded: 1 with tremor during alcohol withdrawal and 14 without tremor that were on medications which can treat tremor.  Of the remaining 806 patients, 123 had subjective report of tremor or tremor on examination. Of these 123 patients, 2 patients (1.6%) carried a diagnosis of Parkinson’s disease. The prevalence of tremor was therefore 15.0%.
The prevalence of tremor in the patient population of the Amyloidosis Center at Boston Medical Center is significantly higher than most estimates of the prevalence of ET in the population-at-large (0.1% to 2.2%). We will use these data to develop a future prospective study to further characterize the tremor and correlate the tremor to specific amyloid subtypes. Nerve conduction studies will help determine whether subclinical neuropathy may be contributing to the development of tremor in these patients. 
Authors/Disclosures
Thomas Ford, MD (University of Massachusetts Medical Center)
PRESENTER 		Dr. Ford has nothing to disclose.
Alexis A. Clay, MD (USC KECK HOSPITAL) No disclosure on file
Michelle Kaku, MD (Icahn School of Medicine at Mount Sinai, Neurology Dept.) Dr. Kaku has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Fatcliffe Harten Galamaga LLP.
Stephanie L. Bissonnette, DO The institution of Dr. Bissonnette has received research support from SAGE Therapeutics. The institution of Dr. Bissonnette has received research support from Huntington's Disease Society of America. The institution of Dr. Bissonnette has received research support from CHDI Foundation.